Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients

The Medicines Company

Overview

To monitor the frequency of the development of thrombocytopenia in patients with Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome receiving bivalirudin during Percutaneous Coronary Intervention

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Conditions

Heparin-Induced Thrombocytopenia Heparin-induced Thrombocytopenia and Thrombosis Syndrome

Interventions

bivalirudinDRUG

Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinically Documented History of HIT/HITTS * Suspicion of HIT/HITTS Exclusion Criteria: * Bleeding Diathesis * Ischemic Stroke * Chronic Thrombocytopenia * Hematologic Malignancy * Contraindication to bivalirudin * Pregnant or nursing mothers

Locations (1)

Duke Clinical Research Institute

Durham, North Carolina, United States

Outcomes

Primary Outcomes

Platelet counts

Time frame: 6, 12, 24, 48 Hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.